Vysis to expand HER-2 testing kit outside U.S.

Roche (SWX:ROCZ) will expand the use of VYSI's PathVysion HER2 breast cancer test kit with Herceptin outside the U.S. ROCZ markets Herceptin, an anti-HER-2 monoclonal antibody developed by Genentech (...